Click on ‘Explanation about the score’ sign next to each entry to expand and learn more.
The company should publicly commit to human rights in relation to product development and marketing, by adopting an official human rights policy statement recognising the right to the highest attainable standard of health. The company should endeavour to integrate human rights into its strategies, policies, programmes, projects, and activities.
The company should also have a publicly available global access plan for their Covid-19 product, based on human rights standards, with measurable targets and lines of accountability.
Finlay has agreed to collaborate on vaccine trials and to open licensing for other countries to produce Soberana 02. Venezuela has taken up the offer. Its open licensing, open patents approach will contribute to global access to the vaccine.
The ‘our values’ section on Finlay’s website refers to ‘good practices for the production of vaccines with a business, social and environmental security approach’. There is no mention of human rights.
The company should constructively engage with international initiatives for the equitable distribution of vaccines and therapeutics, such as the Covid-19 Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP), and the ACT Accelerator (COVAX). The company should also publicly commit to not enforcing the exclusive rights of Covid-19 related patents, and enter into non-exclusive, transparent licensing agreements for its Covid-19 products with other companies.
At the Summit for Vaccine Internationalism (led by the Global South) Cuba committed to open licensing technology for Soberana 2 (including patents & know-how). KEI encouraged Cuba to collaborate with C-TAP. Hopefully Finlay will commit to one of these licensing mechanisms once Soberana 02 receives WHO regulatory approval.
Cuba’s biotech sector is public and it has declared itself to be favourable to the general waiving of monopolies for Covid-19 products. Its patents are therefore public and ‘free to facilitate tech transfer’. Soberana 02 is known as an ‘open-source vaccine’ and the effect of this is equivalent to the company not enforcing its exclusive patent rights.
Finlay has made offers of open licensing, and stated that they would be ‘open to licensing the intellectual property around the vaccines with a small profit margin’. Iran is already producing the vaccine, and Vietnam, Argentina and Mexico have stated that they hope to produce the Cuban vaccines soon.
The company should engage in efforts to further equitable distribution of Covid-19 vaccines/therapeutics, by equitably distributing its supplies globally, devising fair pricing strategies, and making the active ingredient for its product available to other manufacturers. The company should also engage in full technology transfer to other manufacturers, including the necessary transfer of skills, legal components, knowledge and intellectual property. Where applicable, the company should agree to waive rights in regulatory test data, and refrain from enforcing TRIPS+ measures.
[Only applies to therapeutics]